Last reviewed · How we verify
V930
At a glance
| Generic name | V930 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Test the Tolerability of an Investigational Electroporation Device in Healthy Adults (V930-001) (PHASE1)
- A Study to Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED) (PHASE1)
- V930 First in Man (FIM) Study (V930-002)(COMPLETED) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V930 CI brief — competitive landscape report
- V930 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI